reumatoid artrit epidemiology etiology, pathogenesis ... · epidemiology. etiology, pathogenesis....
TRANSCRIPT
![Page 1: REUMATOID ARTRIT Epidemiology Etiology, pathogenesis ... · Epidemiology. Etiology, pathogenesis. Clinical manifestations. Diagnosis. Prognosis. Treatment . Kristian Stengaard-Pedersen](https://reader031.vdocuments.mx/reader031/viewer/2022021614/5c5ca0c809d3f2a1498b9fbd/html5/thumbnails/1.jpg)
Kristian Stengaard-Pedersen
Department of Rheumatology, Aarhus University Hospital
REUMATOID ARTRIT
Epidemiology
Etiology, pathogenesis
Clinical manifestations
Diagnosis
Prognosis
Treatment
![Page 2: REUMATOID ARTRIT Epidemiology Etiology, pathogenesis ... · Epidemiology. Etiology, pathogenesis. Clinical manifestations. Diagnosis. Prognosis. Treatment . Kristian Stengaard-Pedersen](https://reader031.vdocuments.mx/reader031/viewer/2022021614/5c5ca0c809d3f2a1498b9fbd/html5/thumbnails/2.jpg)
Kristian Stengaard-Pedersen Department of Rheumatology Aarhus University Hospital
Reumatoid arthritisMain conclusions of the Health Technology Assessment Report 2002
of early referral, diagnosis, and pharmacotherapy
![Page 3: REUMATOID ARTRIT Epidemiology Etiology, pathogenesis ... · Epidemiology. Etiology, pathogenesis. Clinical manifestations. Diagnosis. Prognosis. Treatment . Kristian Stengaard-Pedersen](https://reader031.vdocuments.mx/reader031/viewer/2022021614/5c5ca0c809d3f2a1498b9fbd/html5/thumbnails/3.jpg)
HTA - REUMATOID ARTHRITIS A major health problem in Denmark
• Prevalence 35000
• Incidence per year 1700
• Specialist treatment 18000
• Operations yearly 4000
• Disablement pension 50%
• Reduced life expectancy 8-10 years
![Page 4: REUMATOID ARTRIT Epidemiology Etiology, pathogenesis ... · Epidemiology. Etiology, pathogenesis. Clinical manifestations. Diagnosis. Prognosis. Treatment . Kristian Stengaard-Pedersen](https://reader031.vdocuments.mx/reader031/viewer/2022021614/5c5ca0c809d3f2a1498b9fbd/html5/thumbnails/4.jpg)
EPIDEMIOLOGY OF RA• Prevalence 0.5 – 1.0%
• Incidence
M 0.2 – 0.4/1000/year
K 0.1 – 0.2/1000/year
• Peak incidence 50-60 yrs
• Affects 2 - 3 times as many women as men
![Page 5: REUMATOID ARTRIT Epidemiology Etiology, pathogenesis ... · Epidemiology. Etiology, pathogenesis. Clinical manifestations. Diagnosis. Prognosis. Treatment . Kristian Stengaard-Pedersen](https://reader031.vdocuments.mx/reader031/viewer/2022021614/5c5ca0c809d3f2a1498b9fbd/html5/thumbnails/5.jpg)
RHEUMATOID ARTHRITIS
![Page 6: REUMATOID ARTRIT Epidemiology Etiology, pathogenesis ... · Epidemiology. Etiology, pathogenesis. Clinical manifestations. Diagnosis. Prognosis. Treatment . Kristian Stengaard-Pedersen](https://reader031.vdocuments.mx/reader031/viewer/2022021614/5c5ca0c809d3f2a1498b9fbd/html5/thumbnails/6.jpg)
AETIOLOGY
![Page 7: REUMATOID ARTRIT Epidemiology Etiology, pathogenesis ... · Epidemiology. Etiology, pathogenesis. Clinical manifestations. Diagnosis. Prognosis. Treatment . Kristian Stengaard-Pedersen](https://reader031.vdocuments.mx/reader031/viewer/2022021614/5c5ca0c809d3f2a1498b9fbd/html5/thumbnails/7.jpg)
RHEUMATOID ARTHRITISJOINT DAMAGE LEADS TO INFLAMMATION
THE REVERSAL OF THE CLINICAL PARADIGM
Ann Rheum Dis 2009;68:159-62
![Page 8: REUMATOID ARTRIT Epidemiology Etiology, pathogenesis ... · Epidemiology. Etiology, pathogenesis. Clinical manifestations. Diagnosis. Prognosis. Treatment . Kristian Stengaard-Pedersen](https://reader031.vdocuments.mx/reader031/viewer/2022021614/5c5ca0c809d3f2a1498b9fbd/html5/thumbnails/8.jpg)
DEVELOPMENT OF RHEUMATOID ARTHRITIS RISK FACTORSGenes
• Shared epitope, HLA-DRB1 genotype• TNF-alpha receptor genotype polymorphism• RANKL genotypes polymorphism• Female sex• Others
Environment• Cigarette smoking• Hormones• Diet• Infection• OccupationComplex interaction between shared epitope, cigarette smoking, and other factors influence the development of RA
![Page 9: REUMATOID ARTRIT Epidemiology Etiology, pathogenesis ... · Epidemiology. Etiology, pathogenesis. Clinical manifestations. Diagnosis. Prognosis. Treatment . Kristian Stengaard-Pedersen](https://reader031.vdocuments.mx/reader031/viewer/2022021614/5c5ca0c809d3f2a1498b9fbd/html5/thumbnails/9.jpg)
GENETICS
![Page 10: REUMATOID ARTRIT Epidemiology Etiology, pathogenesis ... · Epidemiology. Etiology, pathogenesis. Clinical manifestations. Diagnosis. Prognosis. Treatment . Kristian Stengaard-Pedersen](https://reader031.vdocuments.mx/reader031/viewer/2022021614/5c5ca0c809d3f2a1498b9fbd/html5/thumbnails/10.jpg)
REUMATOID ARTHRITIS GENETICS OF THE MAJOR HISTOCOMPATIBILITYCOMPLEX
• First generation of relatives to RA patients have 16 times higher risk for developing RA than the general population
• A concordance of 15-30% in monozygotic twins and 5% in dizygotic twins
• HLA-DRB1 allele genes are markers for susceptibility and for more severe erosive RA
![Page 11: REUMATOID ARTRIT Epidemiology Etiology, pathogenesis ... · Epidemiology. Etiology, pathogenesis. Clinical manifestations. Diagnosis. Prognosis. Treatment . Kristian Stengaard-Pedersen](https://reader031.vdocuments.mx/reader031/viewer/2022021614/5c5ca0c809d3f2a1498b9fbd/html5/thumbnails/11.jpg)
RA: CONTRIBUTING GENETIC FACTORS
![Page 12: REUMATOID ARTRIT Epidemiology Etiology, pathogenesis ... · Epidemiology. Etiology, pathogenesis. Clinical manifestations. Diagnosis. Prognosis. Treatment . Kristian Stengaard-Pedersen](https://reader031.vdocuments.mx/reader031/viewer/2022021614/5c5ca0c809d3f2a1498b9fbd/html5/thumbnails/12.jpg)
STRUCTURE OF HLA MOLECULES: FUNCTIONAL IMPLICATIONS
![Page 13: REUMATOID ARTRIT Epidemiology Etiology, pathogenesis ... · Epidemiology. Etiology, pathogenesis. Clinical manifestations. Diagnosis. Prognosis. Treatment . Kristian Stengaard-Pedersen](https://reader031.vdocuments.mx/reader031/viewer/2022021614/5c5ca0c809d3f2a1498b9fbd/html5/thumbnails/13.jpg)
![Page 14: REUMATOID ARTRIT Epidemiology Etiology, pathogenesis ... · Epidemiology. Etiology, pathogenesis. Clinical manifestations. Diagnosis. Prognosis. Treatment . Kristian Stengaard-Pedersen](https://reader031.vdocuments.mx/reader031/viewer/2022021614/5c5ca0c809d3f2a1498b9fbd/html5/thumbnails/14.jpg)
GENETICS OF THE MAJOR HISTOCOMPATIBILITY COMPLEX IN RA
The HLA-DRB1 allele genes (0401, 0404, 0101) on chromosome 6 encodes the class II histocompatibility antigens that form the human leucocyte antigen HLA (types) which are markers for susceptability
and for more severe erosive RA
![Page 15: REUMATOID ARTRIT Epidemiology Etiology, pathogenesis ... · Epidemiology. Etiology, pathogenesis. Clinical manifestations. Diagnosis. Prognosis. Treatment . Kristian Stengaard-Pedersen](https://reader031.vdocuments.mx/reader031/viewer/2022021614/5c5ca0c809d3f2a1498b9fbd/html5/thumbnails/15.jpg)
AETHIOLOGY OF RHEUMATOID ARTHRITIS
ENVIRONMENTAL FACTORS
• Infections / autoantigens
• Smoking
• Diet
• Others
![Page 16: REUMATOID ARTRIT Epidemiology Etiology, pathogenesis ... · Epidemiology. Etiology, pathogenesis. Clinical manifestations. Diagnosis. Prognosis. Treatment . Kristian Stengaard-Pedersen](https://reader031.vdocuments.mx/reader031/viewer/2022021614/5c5ca0c809d3f2a1498b9fbd/html5/thumbnails/16.jpg)
SMOOKING
![Page 17: REUMATOID ARTRIT Epidemiology Etiology, pathogenesis ... · Epidemiology. Etiology, pathogenesis. Clinical manifestations. Diagnosis. Prognosis. Treatment . Kristian Stengaard-Pedersen](https://reader031.vdocuments.mx/reader031/viewer/2022021614/5c5ca0c809d3f2a1498b9fbd/html5/thumbnails/17.jpg)
HISTOLOGY RA● Synovial cell proliferation● Leukocyte infiltration● Angiogenesis
Inflammation
Citrullination
Anti-CCP ab
![Page 18: REUMATOID ARTRIT Epidemiology Etiology, pathogenesis ... · Epidemiology. Etiology, pathogenesis. Clinical manifestations. Diagnosis. Prognosis. Treatment . Kristian Stengaard-Pedersen](https://reader031.vdocuments.mx/reader031/viewer/2022021614/5c5ca0c809d3f2a1498b9fbd/html5/thumbnails/18.jpg)
DEIMINATION (CITRULLINATION) OF ARGININE BY PEPTIDYLARGININE DEIMINASE (PAD)
![Page 19: REUMATOID ARTRIT Epidemiology Etiology, pathogenesis ... · Epidemiology. Etiology, pathogenesis. Clinical manifestations. Diagnosis. Prognosis. Treatment . Kristian Stengaard-Pedersen](https://reader031.vdocuments.mx/reader031/viewer/2022021614/5c5ca0c809d3f2a1498b9fbd/html5/thumbnails/19.jpg)
DEIMINATION (CITRULLINATION) OF ARGININE BY PEPTIDYLARGININE DEIMINASE (PAD)
![Page 20: REUMATOID ARTRIT Epidemiology Etiology, pathogenesis ... · Epidemiology. Etiology, pathogenesis. Clinical manifestations. Diagnosis. Prognosis. Treatment . Kristian Stengaard-Pedersen](https://reader031.vdocuments.mx/reader031/viewer/2022021614/5c5ca0c809d3f2a1498b9fbd/html5/thumbnails/20.jpg)
Macrophage phagocytosis of apoptotic neutrophils is compromised by matrix proteins modified by cigarette smoke
and lipid peroxidation productsKirkham PA, Spooner G, Rahman I, Rossi AG
Biochem Biophys Res Commun 2004 21;318:32-7
![Page 21: REUMATOID ARTRIT Epidemiology Etiology, pathogenesis ... · Epidemiology. Etiology, pathogenesis. Clinical manifestations. Diagnosis. Prognosis. Treatment . Kristian Stengaard-Pedersen](https://reader031.vdocuments.mx/reader031/viewer/2022021614/5c5ca0c809d3f2a1498b9fbd/html5/thumbnails/21.jpg)
RELATIVE RISK OF DEVELOPING RA
Arthritis Rheum 2006;54:38-46
![Page 22: REUMATOID ARTRIT Epidemiology Etiology, pathogenesis ... · Epidemiology. Etiology, pathogenesis. Clinical manifestations. Diagnosis. Prognosis. Treatment . Kristian Stengaard-Pedersen](https://reader031.vdocuments.mx/reader031/viewer/2022021614/5c5ca0c809d3f2a1498b9fbd/html5/thumbnails/22.jpg)
A NEW MODEL FOR AN ETIOLOGY OF RACONCLUSIONS
Smoking in the context of HLA-DR SE genes may trigger RA-specific immune reactions to citrullinated proteins
The data suggests an ethiology for RA involving a specific genotype, an environmental provocation, and the induction of specific autoimmunity, all restricted to a distinct subset of RA
Arthritis Rheum 2006;54:38-46
![Page 23: REUMATOID ARTRIT Epidemiology Etiology, pathogenesis ... · Epidemiology. Etiology, pathogenesis. Clinical manifestations. Diagnosis. Prognosis. Treatment . Kristian Stengaard-Pedersen](https://reader031.vdocuments.mx/reader031/viewer/2022021614/5c5ca0c809d3f2a1498b9fbd/html5/thumbnails/23.jpg)
RHEUMATOID ARTHRITISRISK FACTORS
ALCOHOL CONSUMPTION IS ASSOCIATED WITH DECREASED RHEUMATOID ARTHRITIS: RESULTS FROM TWO
SCANDINAVIAN CASE-CONTROL STUDIES
ANN RHEUM DIS 2009;68:222-7
![Page 24: REUMATOID ARTRIT Epidemiology Etiology, pathogenesis ... · Epidemiology. Etiology, pathogenesis. Clinical manifestations. Diagnosis. Prognosis. Treatment . Kristian Stengaard-Pedersen](https://reader031.vdocuments.mx/reader031/viewer/2022021614/5c5ca0c809d3f2a1498b9fbd/html5/thumbnails/24.jpg)
ALCOHOL CONSUMPTION, HLA-DRB1 SE ALLELES AND RISK OF ACPA POSITIVE RA
Ann Rheum Dis 2009;68:222-7
![Page 25: REUMATOID ARTRIT Epidemiology Etiology, pathogenesis ... · Epidemiology. Etiology, pathogenesis. Clinical manifestations. Diagnosis. Prognosis. Treatment . Kristian Stengaard-Pedersen](https://reader031.vdocuments.mx/reader031/viewer/2022021614/5c5ca0c809d3f2a1498b9fbd/html5/thumbnails/25.jpg)
DEVELOPMENT OF RHEUMATOID ARTHRITIS RISK FACTORS
Genes• Shared epitope, HLA-DRB1 genotype• TNF-alpha receptor genotype polymorphism• RANKL genotypes polymorphism• Female sex• Others
Environment• Cigarette smoking• Hormones• Diet• Infection• OccupationComplex interaction between shared epitope, cigarette smoking, and other factors influence the development of RA
![Page 26: REUMATOID ARTRIT Epidemiology Etiology, pathogenesis ... · Epidemiology. Etiology, pathogenesis. Clinical manifestations. Diagnosis. Prognosis. Treatment . Kristian Stengaard-Pedersen](https://reader031.vdocuments.mx/reader031/viewer/2022021614/5c5ca0c809d3f2a1498b9fbd/html5/thumbnails/26.jpg)
PATHOGENESIS
![Page 27: REUMATOID ARTRIT Epidemiology Etiology, pathogenesis ... · Epidemiology. Etiology, pathogenesis. Clinical manifestations. Diagnosis. Prognosis. Treatment . Kristian Stengaard-Pedersen](https://reader031.vdocuments.mx/reader031/viewer/2022021614/5c5ca0c809d3f2a1498b9fbd/html5/thumbnails/27.jpg)
RHEUMATOID ARTHRITISINFLAMMATION LEADS TO JOINT DESTRUCTION
THE TRADITIONAL PARADIGM
● Innate immune system triggered − MBL, NK cells, macrophages
● Adaptive immune system triggered − Cells: APC, T- and B-lymphocytes
Humoral: AB, immune complexes, complement
● Synovial cellssynoviocytes,fibroblasts,endothelial cells
● Osteoclasts, chondrocytes
Ann Rheum Dis 2009;68:159-62
![Page 28: REUMATOID ARTRIT Epidemiology Etiology, pathogenesis ... · Epidemiology. Etiology, pathogenesis. Clinical manifestations. Diagnosis. Prognosis. Treatment . Kristian Stengaard-Pedersen](https://reader031.vdocuments.mx/reader031/viewer/2022021614/5c5ca0c809d3f2a1498b9fbd/html5/thumbnails/28.jpg)
RHEUMATOID ARTHRITIS
![Page 29: REUMATOID ARTRIT Epidemiology Etiology, pathogenesis ... · Epidemiology. Etiology, pathogenesis. Clinical manifestations. Diagnosis. Prognosis. Treatment . Kristian Stengaard-Pedersen](https://reader031.vdocuments.mx/reader031/viewer/2022021614/5c5ca0c809d3f2a1498b9fbd/html5/thumbnails/29.jpg)
HISTOLOGYSynovial cell proliferationLeukocyte infiltrationAngiogenesis
![Page 30: REUMATOID ARTRIT Epidemiology Etiology, pathogenesis ... · Epidemiology. Etiology, pathogenesis. Clinical manifestations. Diagnosis. Prognosis. Treatment . Kristian Stengaard-Pedersen](https://reader031.vdocuments.mx/reader031/viewer/2022021614/5c5ca0c809d3f2a1498b9fbd/html5/thumbnails/30.jpg)
ACTIVATED T CELLS ORCHESTRATE THE INFLAMMATORY RESPONSE IN RA
![Page 31: REUMATOID ARTRIT Epidemiology Etiology, pathogenesis ... · Epidemiology. Etiology, pathogenesis. Clinical manifestations. Diagnosis. Prognosis. Treatment . Kristian Stengaard-Pedersen](https://reader031.vdocuments.mx/reader031/viewer/2022021614/5c5ca0c809d3f2a1498b9fbd/html5/thumbnails/31.jpg)
CYTOKINE NETWORK
![Page 32: REUMATOID ARTRIT Epidemiology Etiology, pathogenesis ... · Epidemiology. Etiology, pathogenesis. Clinical manifestations. Diagnosis. Prognosis. Treatment . Kristian Stengaard-Pedersen](https://reader031.vdocuments.mx/reader031/viewer/2022021614/5c5ca0c809d3f2a1498b9fbd/html5/thumbnails/32.jpg)
CYTOKINE NETWORK
Acute phase proteins
Swollen and tenderjoints
Joint destruction
![Page 33: REUMATOID ARTRIT Epidemiology Etiology, pathogenesis ... · Epidemiology. Etiology, pathogenesis. Clinical manifestations. Diagnosis. Prognosis. Treatment . Kristian Stengaard-Pedersen](https://reader031.vdocuments.mx/reader031/viewer/2022021614/5c5ca0c809d3f2a1498b9fbd/html5/thumbnails/33.jpg)
TNF-alpha inhibitors
Infliximab
Adalimumab
Etanercept
![Page 34: REUMATOID ARTRIT Epidemiology Etiology, pathogenesis ... · Epidemiology. Etiology, pathogenesis. Clinical manifestations. Diagnosis. Prognosis. Treatment . Kristian Stengaard-Pedersen](https://reader031.vdocuments.mx/reader031/viewer/2022021614/5c5ca0c809d3f2a1498b9fbd/html5/thumbnails/34.jpg)
Key Actions Attributed to TNF-α
Choy EHS, Panayi GS. N Engl J Med. 2001;344:907–916.Feldmann M et al. Annu Rev Immunol. 1996;14:397–440.Gravallese EM, Goldring SR. Arthritis Rheum. 2000;43:2143–2151.
![Page 35: REUMATOID ARTRIT Epidemiology Etiology, pathogenesis ... · Epidemiology. Etiology, pathogenesis. Clinical manifestations. Diagnosis. Prognosis. Treatment . Kristian Stengaard-Pedersen](https://reader031.vdocuments.mx/reader031/viewer/2022021614/5c5ca0c809d3f2a1498b9fbd/html5/thumbnails/35.jpg)
T-LYMFOCYTE MODULATOR
ABATACEPT• Selective Co-stimulator Modulator
![Page 36: REUMATOID ARTRIT Epidemiology Etiology, pathogenesis ... · Epidemiology. Etiology, pathogenesis. Clinical manifestations. Diagnosis. Prognosis. Treatment . Kristian Stengaard-Pedersen](https://reader031.vdocuments.mx/reader031/viewer/2022021614/5c5ca0c809d3f2a1498b9fbd/html5/thumbnails/36.jpg)
ACTIVATION OF T CELLS IN RA
![Page 37: REUMATOID ARTRIT Epidemiology Etiology, pathogenesis ... · Epidemiology. Etiology, pathogenesis. Clinical manifestations. Diagnosis. Prognosis. Treatment . Kristian Stengaard-Pedersen](https://reader031.vdocuments.mx/reader031/viewer/2022021614/5c5ca0c809d3f2a1498b9fbd/html5/thumbnails/37.jpg)
ABATACEPT CHIMERIC FUSION PROTEIN OF HUMAN CTLA4 MOLECULE AND HUMAN IgG
![Page 38: REUMATOID ARTRIT Epidemiology Etiology, pathogenesis ... · Epidemiology. Etiology, pathogenesis. Clinical manifestations. Diagnosis. Prognosis. Treatment . Kristian Stengaard-Pedersen](https://reader031.vdocuments.mx/reader031/viewer/2022021614/5c5ca0c809d3f2a1498b9fbd/html5/thumbnails/38.jpg)
ACTIVATION OF T CELLS IN RA
![Page 39: REUMATOID ARTRIT Epidemiology Etiology, pathogenesis ... · Epidemiology. Etiology, pathogenesis. Clinical manifestations. Diagnosis. Prognosis. Treatment . Kristian Stengaard-Pedersen](https://reader031.vdocuments.mx/reader031/viewer/2022021614/5c5ca0c809d3f2a1498b9fbd/html5/thumbnails/39.jpg)
THE ROLE OF B-CELLS IN RA
![Page 40: REUMATOID ARTRIT Epidemiology Etiology, pathogenesis ... · Epidemiology. Etiology, pathogenesis. Clinical manifestations. Diagnosis. Prognosis. Treatment . Kristian Stengaard-Pedersen](https://reader031.vdocuments.mx/reader031/viewer/2022021614/5c5ca0c809d3f2a1498b9fbd/html5/thumbnails/40.jpg)
![Page 41: REUMATOID ARTRIT Epidemiology Etiology, pathogenesis ... · Epidemiology. Etiology, pathogenesis. Clinical manifestations. Diagnosis. Prognosis. Treatment . Kristian Stengaard-Pedersen](https://reader031.vdocuments.mx/reader031/viewer/2022021614/5c5ca0c809d3f2a1498b9fbd/html5/thumbnails/41.jpg)
RHEUMATOID ARTHRITIS AUTO-ANTIBODIES• Rheumatoid factors• Anti-CCP antibodies• Anti-BIP/p68 antibodies• Anti-calpastatin• Anti-collagen type II antibodies• Anti-GPI antibodies• Anti-RA33 antibodies• Anti-SA antibodies• ANA• ANCA
S Rantapää -Dahlqvist. Scand J Rheumatol 2005;34:83–96
![Page 42: REUMATOID ARTRIT Epidemiology Etiology, pathogenesis ... · Epidemiology. Etiology, pathogenesis. Clinical manifestations. Diagnosis. Prognosis. Treatment . Kristian Stengaard-Pedersen](https://reader031.vdocuments.mx/reader031/viewer/2022021614/5c5ca0c809d3f2a1498b9fbd/html5/thumbnails/42.jpg)
RHEUMATOID FACTORS
![Page 43: REUMATOID ARTRIT Epidemiology Etiology, pathogenesis ... · Epidemiology. Etiology, pathogenesis. Clinical manifestations. Diagnosis. Prognosis. Treatment . Kristian Stengaard-Pedersen](https://reader031.vdocuments.mx/reader031/viewer/2022021614/5c5ca0c809d3f2a1498b9fbd/html5/thumbnails/43.jpg)
B-LYMFOCYTE MODULATOR
RITUXIMAB• Selective anti-CD20 antibodies
![Page 44: REUMATOID ARTRIT Epidemiology Etiology, pathogenesis ... · Epidemiology. Etiology, pathogenesis. Clinical manifestations. Diagnosis. Prognosis. Treatment . Kristian Stengaard-Pedersen](https://reader031.vdocuments.mx/reader031/viewer/2022021614/5c5ca0c809d3f2a1498b9fbd/html5/thumbnails/44.jpg)
TARGETING THE LYMPHOCYTES IN THE TREATMENT OF AUTOIMMUNE DISEASES
1 = Anti-CD20, DAS of B-cells2 = Anti-CD40L, inhibition of B-cell activation3 = Anti-cytokine BlyS inhibition of B-cell survival4 = LJP394, B-cell functional inactivation
Looney RJ et al. Curr Opin Rheumatol. 2004;16:180-5
![Page 45: REUMATOID ARTRIT Epidemiology Etiology, pathogenesis ... · Epidemiology. Etiology, pathogenesis. Clinical manifestations. Diagnosis. Prognosis. Treatment . Kristian Stengaard-Pedersen](https://reader031.vdocuments.mx/reader031/viewer/2022021614/5c5ca0c809d3f2a1498b9fbd/html5/thumbnails/45.jpg)
Cytokine Signaling PathwaysInvolved in RA
Choy EHS, Panayi GS. N Engl J Med 2001;344:907-916. ©2001, Massachusetts Medical Society. All rights reserved.
TNF-aIL-1IL-6
IFN-gIL-12
IL-4IL-10
Macrophage
RF
IL-4IL-6IL-10Plasma
cell
B cell
Interferon-g
Th0
Th2
Synovium
CD4 + T cell
Osteoclast FibroblastChondrocyte
Production of metalloproteinases andother effector molecules
Migration of polymorphonuclear cells
Erosion of bone and cartilage
![Page 46: REUMATOID ARTRIT Epidemiology Etiology, pathogenesis ... · Epidemiology. Etiology, pathogenesis. Clinical manifestations. Diagnosis. Prognosis. Treatment . Kristian Stengaard-Pedersen](https://reader031.vdocuments.mx/reader031/viewer/2022021614/5c5ca0c809d3f2a1498b9fbd/html5/thumbnails/46.jpg)
BONE REMODELING
![Page 47: REUMATOID ARTRIT Epidemiology Etiology, pathogenesis ... · Epidemiology. Etiology, pathogenesis. Clinical manifestations. Diagnosis. Prognosis. Treatment . Kristian Stengaard-Pedersen](https://reader031.vdocuments.mx/reader031/viewer/2022021614/5c5ca0c809d3f2a1498b9fbd/html5/thumbnails/47.jpg)
BONE REMODELING
BONE RESORPTIONOsteoclastic activity, stimulated by PTH, cytokines (IL-1, TNF-alpha), inhibited by calcitonin, sex steroids and other cytokines
BONE FORMATIONOsteoblast secrets osteoid that is mineralized by hydroxyapatite. Stimulated by PTH, sex steroids, IGF-1 and cytokines
![Page 48: REUMATOID ARTRIT Epidemiology Etiology, pathogenesis ... · Epidemiology. Etiology, pathogenesis. Clinical manifestations. Diagnosis. Prognosis. Treatment . Kristian Stengaard-Pedersen](https://reader031.vdocuments.mx/reader031/viewer/2022021614/5c5ca0c809d3f2a1498b9fbd/html5/thumbnails/48.jpg)
RHEUMATOID ARTHRITIS
CLINICAL MANIFESTATIONS
![Page 49: REUMATOID ARTRIT Epidemiology Etiology, pathogenesis ... · Epidemiology. Etiology, pathogenesis. Clinical manifestations. Diagnosis. Prognosis. Treatment . Kristian Stengaard-Pedersen](https://reader031.vdocuments.mx/reader031/viewer/2022021614/5c5ca0c809d3f2a1498b9fbd/html5/thumbnails/49.jpg)
RHEUMATOID ARTHRITIS
6 months 2 years
![Page 50: REUMATOID ARTRIT Epidemiology Etiology, pathogenesis ... · Epidemiology. Etiology, pathogenesis. Clinical manifestations. Diagnosis. Prognosis. Treatment . Kristian Stengaard-Pedersen](https://reader031.vdocuments.mx/reader031/viewer/2022021614/5c5ca0c809d3f2a1498b9fbd/html5/thumbnails/50.jpg)
RHEUMATOID ARTHRITIS6 months 1 year
![Page 51: REUMATOID ARTRIT Epidemiology Etiology, pathogenesis ... · Epidemiology. Etiology, pathogenesis. Clinical manifestations. Diagnosis. Prognosis. Treatment . Kristian Stengaard-Pedersen](https://reader031.vdocuments.mx/reader031/viewer/2022021614/5c5ca0c809d3f2a1498b9fbd/html5/thumbnails/51.jpg)
RHEUMATOID ARTHRITIS4 years
![Page 52: REUMATOID ARTRIT Epidemiology Etiology, pathogenesis ... · Epidemiology. Etiology, pathogenesis. Clinical manifestations. Diagnosis. Prognosis. Treatment . Kristian Stengaard-Pedersen](https://reader031.vdocuments.mx/reader031/viewer/2022021614/5c5ca0c809d3f2a1498b9fbd/html5/thumbnails/52.jpg)
RHEUMATOID ARTHRITIS
12 years
![Page 53: REUMATOID ARTRIT Epidemiology Etiology, pathogenesis ... · Epidemiology. Etiology, pathogenesis. Clinical manifestations. Diagnosis. Prognosis. Treatment . Kristian Stengaard-Pedersen](https://reader031.vdocuments.mx/reader031/viewer/2022021614/5c5ca0c809d3f2a1498b9fbd/html5/thumbnails/53.jpg)
RHEUMATOID ARTHRITIS20 years
![Page 54: REUMATOID ARTRIT Epidemiology Etiology, pathogenesis ... · Epidemiology. Etiology, pathogenesis. Clinical manifestations. Diagnosis. Prognosis. Treatment . Kristian Stengaard-Pedersen](https://reader031.vdocuments.mx/reader031/viewer/2022021614/5c5ca0c809d3f2a1498b9fbd/html5/thumbnails/54.jpg)
RHEUMATOID ARTHRITIS
![Page 55: REUMATOID ARTRIT Epidemiology Etiology, pathogenesis ... · Epidemiology. Etiology, pathogenesis. Clinical manifestations. Diagnosis. Prognosis. Treatment . Kristian Stengaard-Pedersen](https://reader031.vdocuments.mx/reader031/viewer/2022021614/5c5ca0c809d3f2a1498b9fbd/html5/thumbnails/55.jpg)
RHEUMATOID ARTHRITIS
![Page 56: REUMATOID ARTRIT Epidemiology Etiology, pathogenesis ... · Epidemiology. Etiology, pathogenesis. Clinical manifestations. Diagnosis. Prognosis. Treatment . Kristian Stengaard-Pedersen](https://reader031.vdocuments.mx/reader031/viewer/2022021614/5c5ca0c809d3f2a1498b9fbd/html5/thumbnails/56.jpg)
RHEUMATOID ARTHRITIS
![Page 57: REUMATOID ARTRIT Epidemiology Etiology, pathogenesis ... · Epidemiology. Etiology, pathogenesis. Clinical manifestations. Diagnosis. Prognosis. Treatment . Kristian Stengaard-Pedersen](https://reader031.vdocuments.mx/reader031/viewer/2022021614/5c5ca0c809d3f2a1498b9fbd/html5/thumbnails/57.jpg)
RHEUMATOID ARTHRITIS
![Page 58: REUMATOID ARTRIT Epidemiology Etiology, pathogenesis ... · Epidemiology. Etiology, pathogenesis. Clinical manifestations. Diagnosis. Prognosis. Treatment . Kristian Stengaard-Pedersen](https://reader031.vdocuments.mx/reader031/viewer/2022021614/5c5ca0c809d3f2a1498b9fbd/html5/thumbnails/58.jpg)
RHEUMATOID ARTHRITIS
![Page 59: REUMATOID ARTRIT Epidemiology Etiology, pathogenesis ... · Epidemiology. Etiology, pathogenesis. Clinical manifestations. Diagnosis. Prognosis. Treatment . Kristian Stengaard-Pedersen](https://reader031.vdocuments.mx/reader031/viewer/2022021614/5c5ca0c809d3f2a1498b9fbd/html5/thumbnails/59.jpg)
RHEUMATOID ARTHRITIS
![Page 60: REUMATOID ARTRIT Epidemiology Etiology, pathogenesis ... · Epidemiology. Etiology, pathogenesis. Clinical manifestations. Diagnosis. Prognosis. Treatment . Kristian Stengaard-Pedersen](https://reader031.vdocuments.mx/reader031/viewer/2022021614/5c5ca0c809d3f2a1498b9fbd/html5/thumbnails/60.jpg)
RHEUMATOID ARTHRITIS
![Page 61: REUMATOID ARTRIT Epidemiology Etiology, pathogenesis ... · Epidemiology. Etiology, pathogenesis. Clinical manifestations. Diagnosis. Prognosis. Treatment . Kristian Stengaard-Pedersen](https://reader031.vdocuments.mx/reader031/viewer/2022021614/5c5ca0c809d3f2a1498b9fbd/html5/thumbnails/61.jpg)
RHEUMATOID ARTHRITIS
![Page 62: REUMATOID ARTRIT Epidemiology Etiology, pathogenesis ... · Epidemiology. Etiology, pathogenesis. Clinical manifestations. Diagnosis. Prognosis. Treatment . Kristian Stengaard-Pedersen](https://reader031.vdocuments.mx/reader031/viewer/2022021614/5c5ca0c809d3f2a1498b9fbd/html5/thumbnails/62.jpg)
RHEUMATOID ARTHRITIS
![Page 63: REUMATOID ARTRIT Epidemiology Etiology, pathogenesis ... · Epidemiology. Etiology, pathogenesis. Clinical manifestations. Diagnosis. Prognosis. Treatment . Kristian Stengaard-Pedersen](https://reader031.vdocuments.mx/reader031/viewer/2022021614/5c5ca0c809d3f2a1498b9fbd/html5/thumbnails/63.jpg)
REUMATOID NODULI
![Page 64: REUMATOID ARTRIT Epidemiology Etiology, pathogenesis ... · Epidemiology. Etiology, pathogenesis. Clinical manifestations. Diagnosis. Prognosis. Treatment . Kristian Stengaard-Pedersen](https://reader031.vdocuments.mx/reader031/viewer/2022021614/5c5ca0c809d3f2a1498b9fbd/html5/thumbnails/64.jpg)
REUMATOID NODULI
![Page 65: REUMATOID ARTRIT Epidemiology Etiology, pathogenesis ... · Epidemiology. Etiology, pathogenesis. Clinical manifestations. Diagnosis. Prognosis. Treatment . Kristian Stengaard-Pedersen](https://reader031.vdocuments.mx/reader031/viewer/2022021614/5c5ca0c809d3f2a1498b9fbd/html5/thumbnails/65.jpg)
REUMATOID ARTHRITISKARPALTUNNELSYNDROM
![Page 66: REUMATOID ARTRIT Epidemiology Etiology, pathogenesis ... · Epidemiology. Etiology, pathogenesis. Clinical manifestations. Diagnosis. Prognosis. Treatment . Kristian Stengaard-Pedersen](https://reader031.vdocuments.mx/reader031/viewer/2022021614/5c5ca0c809d3f2a1498b9fbd/html5/thumbnails/66.jpg)
REUMATOID ARTHRITISEPISCLERITIS
![Page 67: REUMATOID ARTRIT Epidemiology Etiology, pathogenesis ... · Epidemiology. Etiology, pathogenesis. Clinical manifestations. Diagnosis. Prognosis. Treatment . Kristian Stengaard-Pedersen](https://reader031.vdocuments.mx/reader031/viewer/2022021614/5c5ca0c809d3f2a1498b9fbd/html5/thumbnails/67.jpg)
REUMATOID ARTHRITISNODULES IN THE LUNGS
![Page 68: REUMATOID ARTRIT Epidemiology Etiology, pathogenesis ... · Epidemiology. Etiology, pathogenesis. Clinical manifestations. Diagnosis. Prognosis. Treatment . Kristian Stengaard-Pedersen](https://reader031.vdocuments.mx/reader031/viewer/2022021614/5c5ca0c809d3f2a1498b9fbd/html5/thumbnails/68.jpg)
RHEUMATOID ARTHRITIS
![Page 69: REUMATOID ARTRIT Epidemiology Etiology, pathogenesis ... · Epidemiology. Etiology, pathogenesis. Clinical manifestations. Diagnosis. Prognosis. Treatment . Kristian Stengaard-Pedersen](https://reader031.vdocuments.mx/reader031/viewer/2022021614/5c5ca0c809d3f2a1498b9fbd/html5/thumbnails/69.jpg)
REUMATOID ARTHRITISEkstraartikulære manifestationer
![Page 70: REUMATOID ARTRIT Epidemiology Etiology, pathogenesis ... · Epidemiology. Etiology, pathogenesis. Clinical manifestations. Diagnosis. Prognosis. Treatment . Kristian Stengaard-Pedersen](https://reader031.vdocuments.mx/reader031/viewer/2022021614/5c5ca0c809d3f2a1498b9fbd/html5/thumbnails/70.jpg)
KLINISKE MANIFESTATIONER VED REUMATOID ARTHRITIS
Polyarthritis Ekstraartikulære manifestationer
hænder, håndledfødder, fodledknæledhofteledcolumna cervicalisandre led
tenosynovitis, bursitismyopatinoduli rheumaticivasculitislunger, pleuraehjerte, pericardiumnervesystemøjnenyrerlymfeknudesvulstalmene symptomerosteoporosem.fl.
![Page 71: REUMATOID ARTRIT Epidemiology Etiology, pathogenesis ... · Epidemiology. Etiology, pathogenesis. Clinical manifestations. Diagnosis. Prognosis. Treatment . Kristian Stengaard-Pedersen](https://reader031.vdocuments.mx/reader031/viewer/2022021614/5c5ca0c809d3f2a1498b9fbd/html5/thumbnails/71.jpg)
RHEUMATOID ARTHRITIS
DISEASE COURSE
![Page 72: REUMATOID ARTRIT Epidemiology Etiology, pathogenesis ... · Epidemiology. Etiology, pathogenesis. Clinical manifestations. Diagnosis. Prognosis. Treatment . Kristian Stengaard-Pedersen](https://reader031.vdocuments.mx/reader031/viewer/2022021614/5c5ca0c809d3f2a1498b9fbd/html5/thumbnails/72.jpg)
![Page 73: REUMATOID ARTRIT Epidemiology Etiology, pathogenesis ... · Epidemiology. Etiology, pathogenesis. Clinical manifestations. Diagnosis. Prognosis. Treatment . Kristian Stengaard-Pedersen](https://reader031.vdocuments.mx/reader031/viewer/2022021614/5c5ca0c809d3f2a1498b9fbd/html5/thumbnails/73.jpg)
Seve
rity
(arb
itrar
y un
its)
0
Duration of Disease (years)
5 10
15
20
25
30
Early RA Intermediate Late
Graph: Adapted from Kirwan JR. J Rheumatol 2001;28:881-886.Photo: Copyright © American College of Rheumatology.
InflammationDisabilityRadiographs
© ACR
RA Progression
![Page 74: REUMATOID ARTRIT Epidemiology Etiology, pathogenesis ... · Epidemiology. Etiology, pathogenesis. Clinical manifestations. Diagnosis. Prognosis. Treatment . Kristian Stengaard-Pedersen](https://reader031.vdocuments.mx/reader031/viewer/2022021614/5c5ca0c809d3f2a1498b9fbd/html5/thumbnails/74.jpg)
RHEUMATOID ARTHRITIS
DIAGNOSIS
![Page 75: REUMATOID ARTRIT Epidemiology Etiology, pathogenesis ... · Epidemiology. Etiology, pathogenesis. Clinical manifestations. Diagnosis. Prognosis. Treatment . Kristian Stengaard-Pedersen](https://reader031.vdocuments.mx/reader031/viewer/2022021614/5c5ca0c809d3f2a1498b9fbd/html5/thumbnails/75.jpg)
• At least four of the following criteria
• Morning stiffness >1 hour• Arthritis of ≥3 joint areas• Arthritis of hand joints• Symmetric arthritis
• Rheumatoid nodules• Serum rheumatoid factor• Radiographic changes
Diagnosis of Rheumatoid ArthritisAmerican College of Rheumatology (ACR) Criteria
Arnett FC et al. Arthritis Rheum. 1988;31:315–324.
Must be presentfor at least 6 weeks
![Page 76: REUMATOID ARTRIT Epidemiology Etiology, pathogenesis ... · Epidemiology. Etiology, pathogenesis. Clinical manifestations. Diagnosis. Prognosis. Treatment . Kristian Stengaard-Pedersen](https://reader031.vdocuments.mx/reader031/viewer/2022021614/5c5ca0c809d3f2a1498b9fbd/html5/thumbnails/76.jpg)
RHEUMATOID ARTHRITIS AUTO-ANTIBODIES DIAGNOSTIC AND PROGNOSTIC VALUES
• Rheumatoid factor (RF)
IgG-, IgA, and IgG-M-RF
• Anti-cyclic citrullinated peptide antibodies
Anti-CCP ab
IgM-RF and anti-CCP ab have the same diagnostic sensitivity but for specific early diagnosis and prognosticating radiographically destructive joint disease anti-CCP seems better than IgM-RF
![Page 77: REUMATOID ARTRIT Epidemiology Etiology, pathogenesis ... · Epidemiology. Etiology, pathogenesis. Clinical manifestations. Diagnosis. Prognosis. Treatment . Kristian Stengaard-Pedersen](https://reader031.vdocuments.mx/reader031/viewer/2022021614/5c5ca0c809d3f2a1498b9fbd/html5/thumbnails/77.jpg)
RHEUMATOID ARTHRITIS
PROGNOSIS
![Page 78: REUMATOID ARTRIT Epidemiology Etiology, pathogenesis ... · Epidemiology. Etiology, pathogenesis. Clinical manifestations. Diagnosis. Prognosis. Treatment . Kristian Stengaard-Pedersen](https://reader031.vdocuments.mx/reader031/viewer/2022021614/5c5ca0c809d3f2a1498b9fbd/html5/thumbnails/78.jpg)
The Natural History of Rheumatoid Arthritis
Work disability in RA
Study N Disabled %
Years After Disease Onset
Makisara 405 50 10
Yelin (1987) 822 50 10
Reisine (1989) 206 43 >5
Wolfe (1994) 826 25 12.5
Approximately 50% is disabled after 10 years
J. Rheumatol 1996: (suppl 44) 23:13-22, Frederick Wolfe
![Page 79: REUMATOID ARTRIT Epidemiology Etiology, pathogenesis ... · Epidemiology. Etiology, pathogenesis. Clinical manifestations. Diagnosis. Prognosis. Treatment . Kristian Stengaard-Pedersen](https://reader031.vdocuments.mx/reader031/viewer/2022021614/5c5ca0c809d3f2a1498b9fbd/html5/thumbnails/79.jpg)
10 YEARS SURVIVAL ACCORDING TO QUANTITATIVE MARKERS IN RHEUMATOID ARTHRITIS
Pincus T, Callahan LF, Vaughn WK.J Rheumatol 1987 Apr;14(2):240-51
![Page 80: REUMATOID ARTRIT Epidemiology Etiology, pathogenesis ... · Epidemiology. Etiology, pathogenesis. Clinical manifestations. Diagnosis. Prognosis. Treatment . Kristian Stengaard-Pedersen](https://reader031.vdocuments.mx/reader031/viewer/2022021614/5c5ca0c809d3f2a1498b9fbd/html5/thumbnails/80.jpg)
Rheumatoid arthritis
Prognosis year 2000
• Irreversible joint damage after 2year
• Disablement pension, 50% after 10 yrs
• Reduced life time, approx. 8 years
![Page 81: REUMATOID ARTRIT Epidemiology Etiology, pathogenesis ... · Epidemiology. Etiology, pathogenesis. Clinical manifestations. Diagnosis. Prognosis. Treatment . Kristian Stengaard-Pedersen](https://reader031.vdocuments.mx/reader031/viewer/2022021614/5c5ca0c809d3f2a1498b9fbd/html5/thumbnails/81.jpg)
Rheumatoid arthritisPrognostic factors
● Many joints affected at start of disease● Rapidly erosive progression● Bone marrow oedema on MRI● High RF and anti-CCP● Low social status
![Page 82: REUMATOID ARTRIT Epidemiology Etiology, pathogenesis ... · Epidemiology. Etiology, pathogenesis. Clinical manifestations. Diagnosis. Prognosis. Treatment . Kristian Stengaard-Pedersen](https://reader031.vdocuments.mx/reader031/viewer/2022021614/5c5ca0c809d3f2a1498b9fbd/html5/thumbnails/82.jpg)
RHEUMATOID ARTHRITISProgression of joint damage in early rheumatoid
arthritis: association with HLA-DRB1, rheumatoid
factor, and anti-citrullinated protein antibodies in
relation to different treatment strategiesde Vries-Bouwstra JK, Goekoop-Ruiterman YP, Verpoort KN,
Schreuder GM, Ewals JA, Terwiel JP, Ronday HK, Kerstens PJ, Toes
RE, de Vries RR, Breedveld FC, Dijkmans BA, Huizinga TW, Allaart CF
Arthritis Rheum. 2008 May;58:1293-8
![Page 83: REUMATOID ARTRIT Epidemiology Etiology, pathogenesis ... · Epidemiology. Etiology, pathogenesis. Clinical manifestations. Diagnosis. Prognosis. Treatment . Kristian Stengaard-Pedersen](https://reader031.vdocuments.mx/reader031/viewer/2022021614/5c5ca0c809d3f2a1498b9fbd/html5/thumbnails/83.jpg)
RHEUMATOID ARTHRITISProgression of joint damage
Influence of HLB-DRB1
Arthritis Rheum 2008;58:1293-8
![Page 84: REUMATOID ARTRIT Epidemiology Etiology, pathogenesis ... · Epidemiology. Etiology, pathogenesis. Clinical manifestations. Diagnosis. Prognosis. Treatment . Kristian Stengaard-Pedersen](https://reader031.vdocuments.mx/reader031/viewer/2022021614/5c5ca0c809d3f2a1498b9fbd/html5/thumbnails/84.jpg)
RHEUMATOID ARTHRITISProgression of joint damage
Influence of rheumatoid factor
Arthritis Rheum 2008;58:1293-8
![Page 85: REUMATOID ARTRIT Epidemiology Etiology, pathogenesis ... · Epidemiology. Etiology, pathogenesis. Clinical manifestations. Diagnosis. Prognosis. Treatment . Kristian Stengaard-Pedersen](https://reader031.vdocuments.mx/reader031/viewer/2022021614/5c5ca0c809d3f2a1498b9fbd/html5/thumbnails/85.jpg)
RHEUMATOID ARTHRITISProgression of joint damage
Influence of anti-citrullinated protein antibodies
Arthritis Rheum 2008;58:1293-8
![Page 86: REUMATOID ARTRIT Epidemiology Etiology, pathogenesis ... · Epidemiology. Etiology, pathogenesis. Clinical manifestations. Diagnosis. Prognosis. Treatment . Kristian Stengaard-Pedersen](https://reader031.vdocuments.mx/reader031/viewer/2022021614/5c5ca0c809d3f2a1498b9fbd/html5/thumbnails/86.jpg)
RHEUMATOID ARTHRITISProgression of joint damage
Conclusions● HLA-DRB1 status is associated with
radiographic progression
● Rheumatoid factor and anti-citrullinatedpeptide antibodies are predictive of progressive disease in sequential mono-therapy but not other therapies
● Effective treatment can prevent radiographicprogression even in patients with risk factors for severe damage
Arthritis Rheum 2008;58:1293-8
![Page 87: REUMATOID ARTRIT Epidemiology Etiology, pathogenesis ... · Epidemiology. Etiology, pathogenesis. Clinical manifestations. Diagnosis. Prognosis. Treatment . Kristian Stengaard-Pedersen](https://reader031.vdocuments.mx/reader031/viewer/2022021614/5c5ca0c809d3f2a1498b9fbd/html5/thumbnails/87.jpg)
RHEUMATOID ARTHRITIS
EARLY TREATMENT IS IMPORTANT
![Page 88: REUMATOID ARTRIT Epidemiology Etiology, pathogenesis ... · Epidemiology. Etiology, pathogenesis. Clinical manifestations. Diagnosis. Prognosis. Treatment . Kristian Stengaard-Pedersen](https://reader031.vdocuments.mx/reader031/viewer/2022021614/5c5ca0c809d3f2a1498b9fbd/html5/thumbnails/88.jpg)
RHEUMATOID ARTHRITIS
TREATMENT
![Page 89: REUMATOID ARTRIT Epidemiology Etiology, pathogenesis ... · Epidemiology. Etiology, pathogenesis. Clinical manifestations. Diagnosis. Prognosis. Treatment . Kristian Stengaard-Pedersen](https://reader031.vdocuments.mx/reader031/viewer/2022021614/5c5ca0c809d3f2a1498b9fbd/html5/thumbnails/89.jpg)
RHEUMATOID ARTHRITISTREATMENT
INFLAMMATION (ARTICULAR, EXTRAARTICULAR)● DMARDs: traditional, biologiclas● Glucocorticoids: Local, systemic● NSAIDs: selective, non-selective● Analgesics: paracetamol, opioids
JOIN DESTRUCTION (CERVICAL SPINE, HANDS, FEET, OTHER JOINTS)● Non-pharmacological treatment● Analgesics, NSAIDs● Orthopaedic Surgery: prosthetics, bone fusion,
tendon repair etc.
![Page 90: REUMATOID ARTRIT Epidemiology Etiology, pathogenesis ... · Epidemiology. Etiology, pathogenesis. Clinical manifestations. Diagnosis. Prognosis. Treatment . Kristian Stengaard-Pedersen](https://reader031.vdocuments.mx/reader031/viewer/2022021614/5c5ca0c809d3f2a1498b9fbd/html5/thumbnails/90.jpg)
American College of Rheumatology 2008
recommendations for the use of nonbiologic
and biologic disease-modifying antirheumatic
drugs in rheumatoid arthritis
Saag KG, Teng GG, Patkar NM, Anuntiyo J, Finney C, Curtis JR, Paulus HE, Mudano A, Pisu M, Elkins-Melton M, Outman R, Allison JJ, Suarez Almazor M,Bridges SL Jr, Chatham WW, Hochberg M, MacLean C, Mikuls T, Moreland LW, O'Dell J, Turkiewicz AM, Furst DE; American College of Rheumatology
Arthritis Rheum 2008;59:762-84
![Page 91: REUMATOID ARTRIT Epidemiology Etiology, pathogenesis ... · Epidemiology. Etiology, pathogenesis. Clinical manifestations. Diagnosis. Prognosis. Treatment . Kristian Stengaard-Pedersen](https://reader031.vdocuments.mx/reader031/viewer/2022021614/5c5ca0c809d3f2a1498b9fbd/html5/thumbnails/91.jpg)
RA Duration < 6 months
RA duration 6 – 24 months
RA duration > 24 months
ACRRecommendations
Arthritis Rheum 2008;59:762-84
![Page 92: REUMATOID ARTRIT Epidemiology Etiology, pathogenesis ... · Epidemiology. Etiology, pathogenesis. Clinical manifestations. Diagnosis. Prognosis. Treatment . Kristian Stengaard-Pedersen](https://reader031.vdocuments.mx/reader031/viewer/2022021614/5c5ca0c809d3f2a1498b9fbd/html5/thumbnails/92.jpg)
Management of Rheumatoid Arthritis
Facilitate early diagnosis• Early suspicion• Rapid referral
Consider early, aggressive treatmentSelect appropriate RA therapy
![Page 93: REUMATOID ARTRIT Epidemiology Etiology, pathogenesis ... · Epidemiology. Etiology, pathogenesis. Clinical manifestations. Diagnosis. Prognosis. Treatment . Kristian Stengaard-Pedersen](https://reader031.vdocuments.mx/reader031/viewer/2022021614/5c5ca0c809d3f2a1498b9fbd/html5/thumbnails/93.jpg)
Early Treatment With DMARDs
0
2
4
6
8
10
12
14
0 6 12 18 24Time (months)
Med
ian
Shar
p Sc
ore
*P<0.05 vs. delayed-treatment groupLard LR, et al. Am J Med 2001;111:446-51.
Delayed treatment (median treatment lag time, 123 days; n = 109)Early treatment (median treatment lag time, 15 days; n = 97)
*
![Page 94: REUMATOID ARTRIT Epidemiology Etiology, pathogenesis ... · Epidemiology. Etiology, pathogenesis. Clinical manifestations. Diagnosis. Prognosis. Treatment . Kristian Stengaard-Pedersen](https://reader031.vdocuments.mx/reader031/viewer/2022021614/5c5ca0c809d3f2a1498b9fbd/html5/thumbnails/94.jpg)
Key Therapeutics for RA
GoldPenicillamine
Hydroxychloroquine
Steroids MTXNSAID
1930-40 1950 1960 1980 1990 1998+
Combo
Use of key therapeutics for RA treatment
Biologics
1970
SSZ
![Page 95: REUMATOID ARTRIT Epidemiology Etiology, pathogenesis ... · Epidemiology. Etiology, pathogenesis. Clinical manifestations. Diagnosis. Prognosis. Treatment . Kristian Stengaard-Pedersen](https://reader031.vdocuments.mx/reader031/viewer/2022021614/5c5ca0c809d3f2a1498b9fbd/html5/thumbnails/95.jpg)
REUMATOID ARTRIT PHARMACOLOGICAL TREATMENT
DMARD BiologicalsMethotrexate Infliximab (Remicade)Sulfasalazine Etanercept (Enbrel)Leflunomide Adalimumab (Humira)Aurothiomalate Anakinra (Kineret)Penicillamine Mabthera (Rituximab)HydroxychloroquineAzathioprinCiclosporin
![Page 96: REUMATOID ARTRIT Epidemiology Etiology, pathogenesis ... · Epidemiology. Etiology, pathogenesis. Clinical manifestations. Diagnosis. Prognosis. Treatment . Kristian Stengaard-Pedersen](https://reader031.vdocuments.mx/reader031/viewer/2022021614/5c5ca0c809d3f2a1498b9fbd/html5/thumbnails/96.jpg)
Reasons for Discontinuation From Traditional DMARDs*
Reason for D/C (%)
DMARDTime to D/C
(mo)†Total D/C
(%) Toxicity Inefficacy BothAntimalarial 20 50 14 25 2IM gold 15 57 26 22 2SSZ 10 61 17 36 3MTX 33 34 14 9 2Oral gold 9 70 23 37 1D-pen 14 64 34 23 4Other 8 62 21 36 9Total 16 54 20 25 2
*Retrospective audit of records of 1,132 patients with RA onset between January 1985 and June 1994 who received a total of 2,296 DMARDs; †Median.D/C = Discontinuation; IM = Intramuscular.Adapted from Galindo-Rodriguez G, et al. J Rheumatol 1999;26:2337-2343.
![Page 97: REUMATOID ARTRIT Epidemiology Etiology, pathogenesis ... · Epidemiology. Etiology, pathogenesis. Clinical manifestations. Diagnosis. Prognosis. Treatment . Kristian Stengaard-Pedersen](https://reader031.vdocuments.mx/reader031/viewer/2022021614/5c5ca0c809d3f2a1498b9fbd/html5/thumbnails/97.jpg)
p<0.001 for MTX > Other DMARDs (except AZP and Combination)p<0.05 for CyA < Other DMARDs (except PG and OG)
Cum
ulat
ive
Ret
entio
n R
ates
0 12 24 36 48 60 72 84 96 108120
100
80
60
40
20
0
MethotrexateSulfusalazineChloroquineParenter GoldOral GoldPenicillamineAzathioprineCyclosporineCombination
Time (Months)
Aletaha D, Smolen JS. J Rheumatol 2002;29:1631-1638.
Konventionelle DMARD-lægemidler er effektive Men langvarig behandlingseffekt fastholdes ikke
![Page 98: REUMATOID ARTRIT Epidemiology Etiology, pathogenesis ... · Epidemiology. Etiology, pathogenesis. Clinical manifestations. Diagnosis. Prognosis. Treatment . Kristian Stengaard-Pedersen](https://reader031.vdocuments.mx/reader031/viewer/2022021614/5c5ca0c809d3f2a1498b9fbd/html5/thumbnails/98.jpg)
NØGLEFUNKTIONER
Choy EHS, Panayi GS. N Engl J Med. 2001;344:907–916.Feldmann M et al. Annu Rev Immunol. 1996;14:397–440.Gravallese EM, Goldring SR. Arthritis Rheum. 2000;43:2143–2151.
Hvide blodlegemer
Blodkar
Leveren
Ledslimhinden
TNF-alfa kraftigt betændelsesfremmende samt brusk og knogleødelæggende
![Page 99: REUMATOID ARTRIT Epidemiology Etiology, pathogenesis ... · Epidemiology. Etiology, pathogenesis. Clinical manifestations. Diagnosis. Prognosis. Treatment . Kristian Stengaard-Pedersen](https://reader031.vdocuments.mx/reader031/viewer/2022021614/5c5ca0c809d3f2a1498b9fbd/html5/thumbnails/99.jpg)
Fc Region ofHuman IgG1
Extracellular Domain ofHuman p75 TNF Receptor
Etanercept
•Binds soluble and membrane TNF-α and TNF-β (lymphotoxin)
•Moderate- to high-binding affinity to TNF-α
•Half-life of 4-5 days• Inject sc every 3-4 days•Standard dose only•With MTX or
monotherapy (monotherapy only in EU)
CH3 CH2
SS
SS
SS
SS
SS
SS
![Page 100: REUMATOID ARTRIT Epidemiology Etiology, pathogenesis ... · Epidemiology. Etiology, pathogenesis. Clinical manifestations. Diagnosis. Prognosis. Treatment . Kristian Stengaard-Pedersen](https://reader031.vdocuments.mx/reader031/viewer/2022021614/5c5ca0c809d3f2a1498b9fbd/html5/thumbnails/100.jpg)
TEMPO Study Design: A Three-Arm Trial1
•European and Australian, 92-site, double-blind trial of 686 patients
Reference: 1. The Lancet 2004; 363: 675-81
ENBREL (n=223)
MTX (n=228)
Randomized(N=686)ITT Population (N=682)
Failure on ≥1 DMARDNo recent
MTX ACR-N
24 WeeksTotal Sharp
Score52 Weeks
EndpointsBaseline
Enbrel® (etanercept) + MTX (n=231)
– Withdrawals: MTX, 30%; ENBREL, 24%; ENBREL + MTX, 16%
![Page 101: REUMATOID ARTRIT Epidemiology Etiology, pathogenesis ... · Epidemiology. Etiology, pathogenesis. Clinical manifestations. Diagnosis. Prognosis. Treatment . Kristian Stengaard-Pedersen](https://reader031.vdocuments.mx/reader031/viewer/2022021614/5c5ca0c809d3f2a1498b9fbd/html5/thumbnails/101.jpg)
Reference: 1. The Lancet 2004; 363: 675-81
ACR Response at 52 Weeks1
Analysis using last observation carried forward (LOCF).
% o
f pa
tien
ts r
espo
ndin
g
*p<0.01 vs. MTX †p<0.05 vs. Enbrel‡p<0.01 vs. Enbrel
MTX (n=228)
Enbrel® (etanercept)(n=223)
Enbrel® + MTX (n=231)
ACR 20 ACR 50 ACR 70
7685*†
75
48
69*‡
43
2419
43*‡
100
80
60
40
20
0
![Page 102: REUMATOID ARTRIT Epidemiology Etiology, pathogenesis ... · Epidemiology. Etiology, pathogenesis. Clinical manifestations. Diagnosis. Prognosis. Treatment . Kristian Stengaard-Pedersen](https://reader031.vdocuments.mx/reader031/viewer/2022021614/5c5ca0c809d3f2a1498b9fbd/html5/thumbnails/102.jpg)
Primary Radiographic Endpoint: Change in Total Sharp Score From Baseline at 52 Weeks1
One year value imputed by linear extrapolation if needed.
95% CI(1.08 – 4.51)
95% CI (-0.1 – 1.15)
95% CI (-1.00 – -0.07)
Cha
nge
from
bas
elin
e (m
ean)
Reference: 1. The Lancet 2004; 363: 675-81
*p<0.05 vs. MTX†p<0.01 vs. MTX‡p<0.01 vs. ENBREL
MTX (n = 212)
Enbrel® (etanercept) (n = 212)
Enbrel® + MTX(n = 218)
2.8
0.52*
– 0.54†‡
3.0
2.5
1.0
0.5
0.0
-0.1
2.0
1.5
-0.5
![Page 103: REUMATOID ARTRIT Epidemiology Etiology, pathogenesis ... · Epidemiology. Etiology, pathogenesis. Clinical manifestations. Diagnosis. Prognosis. Treatment . Kristian Stengaard-Pedersen](https://reader031.vdocuments.mx/reader031/viewer/2022021614/5c5ca0c809d3f2a1498b9fbd/html5/thumbnails/103.jpg)
Conclusions: Efficacy
• Benefits of anti-TNF therapy in RA– Rapid, clinically significant, and
sustained improvement in signs and symptoms of disease beyond what is generally seen with traditional DMARDs
– Inhibition of radiographic progression– Improvement in HR QOL and disability
• Overall risk-benefit of TNF inhibitors in RA is strongly positive
![Page 104: REUMATOID ARTRIT Epidemiology Etiology, pathogenesis ... · Epidemiology. Etiology, pathogenesis. Clinical manifestations. Diagnosis. Prognosis. Treatment . Kristian Stengaard-Pedersen](https://reader031.vdocuments.mx/reader031/viewer/2022021614/5c5ca0c809d3f2a1498b9fbd/html5/thumbnails/104.jpg)
SIDE EFFECTS OF BIOLOGICALS
Specific side effects• Injection site reactions • Allergic reactions (infliximab)• Human anti-chimeric antibodies (HACAs: inflixomab)• Leukocyclastic vasculitis (CD4-Ak IDEC-CE9.1)• Pancytopenia (etanercept)• Neurologic symptoms (MS-like; etanercept)
General side effects• Autoimmunity (ANA- and dsDNA-antibodies, SLE) • Infections (tuberculosis, coccidiomycosis)• Malignant disorders
![Page 105: REUMATOID ARTRIT Epidemiology Etiology, pathogenesis ... · Epidemiology. Etiology, pathogenesis. Clinical manifestations. Diagnosis. Prognosis. Treatment . Kristian Stengaard-Pedersen](https://reader031.vdocuments.mx/reader031/viewer/2022021614/5c5ca0c809d3f2a1498b9fbd/html5/thumbnails/105.jpg)
Anti-cytokinbehandling• Anti-TNF-alpha• Mab to IL-1, IL-6, IL-12, IL-15, IL-18, MIF
Receptorblokadebehandling• IL-1Ra • CCR-2 blokade
Celleaktivering• T-lymfocytter (CTLA-4Ig)• B-lymfocytter (anti-CD20)• Monocytter (CCR-2)
BIOLOGISKE LÆGEMIDLERSkræddersyet behandling ved kronisk leddegigt
![Page 106: REUMATOID ARTRIT Epidemiology Etiology, pathogenesis ... · Epidemiology. Etiology, pathogenesis. Clinical manifestations. Diagnosis. Prognosis. Treatment . Kristian Stengaard-Pedersen](https://reader031.vdocuments.mx/reader031/viewer/2022021614/5c5ca0c809d3f2a1498b9fbd/html5/thumbnails/106.jpg)
RHEUMATOID ARTHRITISDMARD treatment
● Early diagnosis, early aggressive DMARD treatment
● Tight control, measurement of disease activity and quick
escalation of DMARD
● DMARD in combination is better than monotherapy
● MTX + TNF-alpha inhibitor is the best combination therapy
● Steroid intraarticular or systemic as bridging therapy
![Page 107: REUMATOID ARTRIT Epidemiology Etiology, pathogenesis ... · Epidemiology. Etiology, pathogenesis. Clinical manifestations. Diagnosis. Prognosis. Treatment . Kristian Stengaard-Pedersen](https://reader031.vdocuments.mx/reader031/viewer/2022021614/5c5ca0c809d3f2a1498b9fbd/html5/thumbnails/107.jpg)
TREATMENT STRATEGY IN RADMARDS
● MTX or (SSZ)
● MTX + SSZ + chloroquineMTX + cyclosporine or MTX + leflunomide
● MTX + TNF inhibitor- Adalimumab- Etanercept- Infliximab
● MTX + Other biologicals
![Page 108: REUMATOID ARTRIT Epidemiology Etiology, pathogenesis ... · Epidemiology. Etiology, pathogenesis. Clinical manifestations. Diagnosis. Prognosis. Treatment . Kristian Stengaard-Pedersen](https://reader031.vdocuments.mx/reader031/viewer/2022021614/5c5ca0c809d3f2a1498b9fbd/html5/thumbnails/108.jpg)
TREATMENT STRATEGY IN RADMARDS CT.
● MTX + TNF inhibitor failure(1-2 used sequentially)
● MTX + abatacept or MTX + rituximab
![Page 109: REUMATOID ARTRIT Epidemiology Etiology, pathogenesis ... · Epidemiology. Etiology, pathogenesis. Clinical manifestations. Diagnosis. Prognosis. Treatment . Kristian Stengaard-Pedersen](https://reader031.vdocuments.mx/reader031/viewer/2022021614/5c5ca0c809d3f2a1498b9fbd/html5/thumbnails/109.jpg)
TECHNIQUE OF GLUCOCORTICOID INJECTION
• Aseptic procedures obligatory
• Skin desinfection with iodinated solution or chlorhexidine alcohol twice before puncture
• Use of sterile gloves, sterile disposable syringes and needles. Handling by ”non-touch-technique”
• Knowledge of anatomy, inflammatory pathology and the injection procedure
• Interval of at least 4-6 weeks between joint injections
• Maximum 3-4 intra-articular injections per year in the same joint
• Injections in bursae and tendon sheets can be repeated up to 3 times with 1-3 weeks interval
![Page 110: REUMATOID ARTRIT Epidemiology Etiology, pathogenesis ... · Epidemiology. Etiology, pathogenesis. Clinical manifestations. Diagnosis. Prognosis. Treatment . Kristian Stengaard-Pedersen](https://reader031.vdocuments.mx/reader031/viewer/2022021614/5c5ca0c809d3f2a1498b9fbd/html5/thumbnails/110.jpg)
MUSCULOSKELETAL ULTRASONOGRAPHY
![Page 111: REUMATOID ARTRIT Epidemiology Etiology, pathogenesis ... · Epidemiology. Etiology, pathogenesis. Clinical manifestations. Diagnosis. Prognosis. Treatment . Kristian Stengaard-Pedersen](https://reader031.vdocuments.mx/reader031/viewer/2022021614/5c5ca0c809d3f2a1498b9fbd/html5/thumbnails/111.jpg)
INDIKATIONER FOR INTRAARTIKULÆRE GLUKOKORTIKOIDINJEKTIONER
Arthritis in a knee joint Arthritis in a MCP-joint
Carpal tunnel syndrome Lateral epicondylitis
![Page 112: REUMATOID ARTRIT Epidemiology Etiology, pathogenesis ... · Epidemiology. Etiology, pathogenesis. Clinical manifestations. Diagnosis. Prognosis. Treatment . Kristian Stengaard-Pedersen](https://reader031.vdocuments.mx/reader031/viewer/2022021614/5c5ca0c809d3f2a1498b9fbd/html5/thumbnails/112.jpg)
RHEUMATOID ARTHRITISTREATMENT
INFLAMMATION (ARTICULAR, EXTRAARTICULAR)● DMARDs: traditional, biologiclas● Glucocorticoids: Local, systemic● NSAIDs: selective, non-selective● Analgesics: paracetamol, opioids
JOIN DESTRUCTION (CERVICAL SPINE, HANDS, FEET, OTHER JOINTS)● Non-pharmacological treatment● Analgesics, NSAIDs● Orthopaedic Surgery: prosthetics, bone fusion,
tendon repair etc.
![Page 113: REUMATOID ARTRIT Epidemiology Etiology, pathogenesis ... · Epidemiology. Etiology, pathogenesis. Clinical manifestations. Diagnosis. Prognosis. Treatment . Kristian Stengaard-Pedersen](https://reader031.vdocuments.mx/reader031/viewer/2022021614/5c5ca0c809d3f2a1498b9fbd/html5/thumbnails/113.jpg)
Kristian Stengaard-Pedersen
Department of Rheumatology, Aarhus University Hospital
RHEUMATOID ARTHRITIS
THANK YOU FOR YOUR ATTENTION!